{"id":10162,"date":"2012-04-22T08:52:47","date_gmt":"2012-04-22T08:52:47","guid":{"rendered":"http:\/\/cardiophile.org\/?p=6912"},"modified":"2012-04-22T08:52:47","modified_gmt":"2012-04-22T08:52:47","slug":"rivaroxaban-2","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/","title":{"rendered":"Rivaroxaban a direct specific competitive factor Xa inhibitor"},"content":{"rendered":"<p><iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/_7t2TLXnkmY\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\"><\/iframe><\/p>\n<h2><span style=\"color: #008000;\">Rivaroxaban a direct specific competitive factor Xa inhibitor<\/span><\/h2>\n<p>Rivaroxaban is direct, specific, competitive factor Xa inhibitor and it has a half life of five to thirteen hours. One third of the drug is cleared directly by the kidneys while two third is metabolized by the cytochrome P 450 enzymes. Rivaroxaban is administered once daily by oral route. There is no need for therapeutic monitoring like warfarin. Rivaroxaban was compared with warfarin in a double blind randomized control trial known as ROCKET-AF [1]. Warfarin was maintained at a target INR (international normalized ratio of prothrombin time) between 2 to 3. Around fourteen thousand patients with nonvalvar atrial fibrillation and additional risk factors (two or three of the following: congestive heart failure, hypertension, age seventy five or above, diabetes mellitus) or with a history of stroke, TIA (transient ischemic attack) or systemic embolism were included in the study. The dosage of rivaroxaban was 20 milligrams daily (15 milligrams daily for those with creatinine clearance between 30 and 49 milli liters per minute). Patients were monitored monthly and standard care guidelines were followed. The primary endpoint was stroke or non central nervous system systemic embolism. The cumulative event rate was 1.71 percent with rivaroxaban and 2.16 percent with warfarin with P value or non inferiority of &lt;0.001. The investigators found that rivaroxaban is not inferior to warfarin for prevention of stroke and non central nervous system systemic embolism. Rivaroxaban was superior to warfarin while patients were taking the study drug and the bleeding rates as well as other adverse event rates were similar. There was less intracranial hemorrhage and fatal bleeding with rivaroxaban. Finally they concluded that rivaroxaban is an alternative to warfarin for those with moderate or high risk for stroke in atrial fibrillation.<\/p>\n<p><strong><span style=\"color: #0000ff;\">Reference<\/span><\/strong><\/p>\n<ol>\n<li>Manesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, Guohua Pan, Daniel E Singer, Werner Hacke, G\u00fcnter Breithardt, Jonathan L Halperin, Graeme J Hankey, Jonathan P Piccini, Richard C Becker, Christopher C Nessel, John F Paolini, Scott D Berkowitz, Keith A A Fox, Robert M Califf, ROCKET AF Investigators. <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa1009638\">Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation<\/a>. N Engl J Med. 2011 Sep 8;365(10):883-91.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Rivaroxaban is direct, specific, competitive factor Xa inhibitor and it has a half life of five to thirteen hours. <\/p>\n","protected":false},"author":1,"featured_media":36110,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-10162","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rivaroxaban a direct specific competitive factor Xa inhibitor<\/title>\n<meta name=\"description\" content=\"Rivaroxaban a direct specific competitive factor Xa inhibitor: Alternative to warfarin for those with moderate or high risk for stroke in AF.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rivaroxaban a direct specific competitive factor Xa inhibitor\" \/>\n<meta property=\"og:description\" content=\"Rivaroxaban a direct specific competitive factor Xa inhibitor: Alternative to warfarin for those with moderate or high risk for stroke in AF.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2012-04-22T08:52:47+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-2\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Rivaroxaban a direct specific competitive factor Xa inhibitor\",\"datePublished\":\"2012-04-22T08:52:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-2\\\/\"},\"wordCount\":353,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-2\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-2\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-2\\\/\",\"name\":\"Rivaroxaban a direct specific competitive factor Xa inhibitor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-2\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2012-04-22T08:52:47+00:00\",\"description\":\"Rivaroxaban a direct specific competitive factor Xa inhibitor: Alternative to warfarin for those with moderate or high risk for stroke in AF.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-2\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/rivaroxaban-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rivaroxaban a direct specific competitive factor Xa inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rivaroxaban a direct specific competitive factor Xa inhibitor","description":"Rivaroxaban a direct specific competitive factor Xa inhibitor: Alternative to warfarin for those with moderate or high risk for stroke in AF.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/","og_locale":"en_US","og_type":"article","og_title":"Rivaroxaban a direct specific competitive factor Xa inhibitor","og_description":"Rivaroxaban a direct specific competitive factor Xa inhibitor: Alternative to warfarin for those with moderate or high risk for stroke in AF.","og_url":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2012-04-22T08:52:47+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Rivaroxaban a direct specific competitive factor Xa inhibitor","datePublished":"2012-04-22T08:52:47+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/"},"wordCount":353,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/#primaryimage"},"thumbnailUrl":"","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/","url":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/","name":"Rivaroxaban a direct specific competitive factor Xa inhibitor","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/#primaryimage"},"thumbnailUrl":"","datePublished":"2012-04-22T08:52:47+00:00","description":"Rivaroxaban a direct specific competitive factor Xa inhibitor: Alternative to warfarin for those with moderate or high risk for stroke in AF.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/rivaroxaban-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Rivaroxaban a direct specific competitive factor Xa inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/10162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=10162"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/10162\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=10162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=10162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=10162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}